Cargando…
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and ti...
Autores principales: | Wang, Nan, Zhan, Yan, Zhu, Linyu, Hou, Zhibing, Liu, Feng, Song, Pinhong, Qiu, Feng, Wang, Xiaolin, Zou, Xiafei, Wan, Deyun, Qian, Xiaosong, Wang, Shanshan, Guo, Yabi, Yu, Hao, Cui, Miao, Tong, Gangling, Xu, Yunsheng, Zheng, Zhihua, Lu, Yingying, Hong, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368656/ https://www.ncbi.nlm.nih.gov/pubmed/32707096 http://dx.doi.org/10.1016/j.chom.2020.07.005 |
Ejemplares similares
-
Clinical evidence of an interferon–glucocorticoid therapeutic synergy in COVID-19
por: Lu, Yingying, et al.
Publicado: (2021) -
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
por: Zhu, Yufang, et al.
Publicado: (2022) -
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
por: Zhan, Yan, et al.
Publicado: (2021) -
Heparin Prowess: Favorable Vascular–Immune Reprogramming in Pancreatic Cancer
por: Korc, Murray
Publicado: (2023) -
Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response
por: Yang, Mu-qing, et al.
Publicado: (2018)